Clinical Trial: Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With Early-Stage Breast Cancer

U.S., Aug. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07136493) titled 'Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With Early-Stage Breast Cancer' on Aug. 10.

Brief Summary: This clinical trial studies how well circulating tumor deoxyribonucleic acid (ctDNA) based minimal residual disease (MRD) detection works for patients with early-stage breast cancer. MRD refers to a very small number of tumor cells that remain in the body during or after treatment. ctDNA refers to small pieces of DNA that are released into a person's blood by tumor cells as they die. Management of patients after cancer surgery remains a clinical dilemma, particularly for cancer detected at earlier st...